Longeveron to Share 50% of Future FDA Priority Review Voucher Proceeds with Private Placement Investors
LGVN has more than doubled off its 52-week low of $0.475.
Summary
Longeveron announced its 2025 full-year financial results and provided a business update, revealing a significant agreement to provide private placement investors with a 50% interest in the proceeds from a potential future sale of a Pediatric Priority Review Voucher (PRV) if granted for its HLHS program. This news follows the company's 10-K filing minutes earlier, which highlighted substantial doubt about its ability to continue as a going concern due to significant losses and a highly dilutive $15.9 million private placement. For a company with a market capitalization of approximately $20 million, a PRV can be worth $150-205 million, making the concession of 50% of these potential proceeds a material impact on future value capture for existing shareholders. The business update also confirmed the ELPIS II trial for HLHS is on track for Q3 2026 top-line results. Traders will closely monitor the trial's progress and any further developments regarding the company's financial stability and partnering strategy.
At the time of this announcement, LGVN was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $0.48 to $1.92. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.